Clark Capital Management Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Clark Capital Management Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-64,978	Closed	-$6.48M	–	322
2020 Q1	$6.48M	Sell	64,978 -110,664	-63%	-$14.3M	0.16%	126
2019 Q4	$26.2M	Buy	175,642 +670	+0.4%	+$91.2K	0.55%	61
2019 Q3	$22.4M	Sell	174,972 -65,699	-27%	-$8.81M	0.51%	75
2019 Q2	$34.3M	Buy	240,671 +13,138	+6%	+$1.77M	0.72%	40
2019 Q1	$32.5M	Buy	227,533 +195,951	+620%	+$25.6M	0.78%	43
2018 Q4	$3.92M	Buy	+31,582	New	+$4.69M	0.11%	134

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Clark Capital Management Group's JAZZ Position: Q2 2020 in Review

Clark Capital Management Group sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2020, closing a stake of 64,978 shares — an estimated $6.48M sold.

Clark Capital Management Group first reported a position in JAZZ in Q4 2018 and held it in 6 quarters. The position peaked at $34.3M in Q2 2019. 384 funds tracked by Wall St. Rank hold JAZZ as of Q2 2020.

Clark Capital Management Group reported no remaining Jazz Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Clark Capital Management Group sold 64,978 Jazz Pharmaceuticals shares in Q2 2020, an estimated $6.48M.
Clark Capital Management Group first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 6 quarters.
Clark Capital Management Group's Jazz Pharmaceuticals position peaked at $34.3M in Q2 2019.
384 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2020.

Based on Clark Capital Management Group's 13F filing for Q2 2020, filed 14 Aug 2020.